touchNEUROLOGY had the great pleasure of speaking with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Cleveland, OH, USA) to discuss the phase 2 MCLENA-1 clinical trial rationale, assessing lenalidomide in patients with mild cognitive impairment due to Alzheimer’s Disease.
The abstract entitled ‘Rationale for the MCLENA-1: A Phase II Clinical Trial for the Assessment of Safety, Tolerability, and Efficacy of Lenalidomide in Patients With Mild Cognitive Impairment Due to Alzheimer’s Disease’ was presented at The 15th International Conference for Alzheimer’s & Parkinson’s Diseases (Virtual), March 8-14, 2021.
- Why is lenalidomide considered a potentially promising drug in the treatment of mild cognitive impairment in Alzheimer’s disease? (0:15)
- What is already known about the benefits of lenalidomide and thalidomide in AD? (2:23)
- What are the aims and design of the MCLENA study? (3:05)
- What are the clinical endpoints in the MCLENA study? (4:35)
- What data has been accrued to date? (5:07)
- What future developments do you have planned? (5:35)
Disclosures: Marwan Sabbagh has ownership interest (stock or stock options) in Brain Health Inc, NeuroReserve, NeuroTau, Optimal Cognitive Health Company, uMethod Health, Versanum, Athira; has been a consultant for Alzheon, Neurotrope, Biogen, Cortexyme, Danone, Regeneron, Roche-Genentech, Stage 2 Innovations, Acadia; and has royalties with HarperCollins. Marwan Sabbagh is also part of the speakers bureau for Health and Wellness Partners and Joyce Knapp Communications.
Support: Interview and filming supported by Touch Medical Media.
Filmed as a highlight of AD/PD Virtual 2021.
Share this Video
Related Videos In Alzheimer's Disease & Dementia
Marwan Sabbagh: Approval of Aducanumab for Alzheimer’s Disease
It was a great pleasure to meet up with Marwan Sabbagh (Cleveland Clinic Lerner College of Medicine, Las Vegas, NV, USA), to discuss the recent approval of aducanumab for Alzheimer’s Disease. Aducanumab was granted accelerated approval on June 7 2021, by the U.S. Food and Drug Administration (FDA). Questions: Could you give us a brief […]
Claudia Trenkwalder, EAN 2021: REM Sleep Behaviour Disorder and Neurodegeneration
touchNEUROLOGY was joined by Prof. Claudia Trenkwalder (Paracelsus-Elena-Hospital, Kassel Germany, University Medical Center, Goettingen, Germany) to discuss her EAN presentation looking into REM Sleep Behaviour Disorder and the connection with neurodegeneration. The abstract entitled: ‘REM Sleep Behaviour Disorder (RBD): future implications for neurodegenerative disease’ was presented at the 7th Congress of the European Academy of […]
Ivana Rosenzweig, Sleep and Breathing 2021: The Link Between Sleep Apnoea and Dementia
We were delighted to speak with Dr Ivana Rosenzweig (Sleep and Brain Plasticity Centre, King’s College London, London, UK) around her talk on the ‘Link between sleep apnoea and dementia: the neuroimaging perspective‘, which was presented at the virtual 2021 Sleep and Breathing Conference, 16-17 April, 2021. Questions What is known about the relationship between […]
Journal articles and more to your inbox
Get the latest clinical insights from touchNEUROLOGYSign me up!